Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

LATESTRYL is contraindicated in men with carcinomas of the breast or with known, or suspected, carcinomas of the prostate.

About VANTAS VANTAS(R) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. VANTAS is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any components in VANTAS.

About SUPPRELIN LA

SUPPRELIN(R) LA is a subcutaneous implant indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. It utilizes the hydron implant technology and is specifically designed to provide a continuous release over 12 months of the gonadotropin releasing hormone (GnRH) agonist, histrelin. SUPPRELIN LA is contraindicated in patients with hypersensitivity to GnRH or GnRH analogs.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated wit
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences ... cooperative research and development agreement (CRADA) with Aratana ... the development of TRB-N0224 for the treatment and ... dogs and cats.  Traverse Biosciences has also granted ... the treatment and control of periodontal disease in ...
(Date:5/4/2015)... - The Fight Against Cancer Innovation Trust (FACIT) ... formation of Turnstone Biologics Inc. (Turnstone), a biotechnology ... harness the patient,s own immune system. ... Children,s Hospital of Eastern Ontario ... Institute for Cancer Research (OICR), the Ottawa Hospital ...
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... , , , COVINA, Calif., Aug. ... today announced that Shannon Miller , a 7-time Olympic Medalist and ... in a series of advertising and public awareness campaigns for the company. ... , Considered "The Most Decorated American Gymnast" by ...
... , , ROCKVILLE, ... the release of 5,000 purified human proteins, representing the ... , OriGene,s recombinant proteins are purified ... Mammalian cell expressed proteins are superior to other ...
... , NEW YORK, Aug. 24 NeoStem, Inc. (Amex: ... long-term storage of adult stem cells for future medical need, announced today ... York Department of Taxation and Finance, for the period ending December 31, ... shareholders that, as a result of this designation, they may be eligible ...
Cached Biology Technology:7-Time Olympic Medalist Shannon Miller Endorses StemCyte 2NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 2NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 3
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2
... abundant biomass material on Earth, and therefore represents an ... production of advance biofuels. A major roadblock, however, has ... the U.S. Department of Energy (DOE),s Joint BioEnergy Institute ... roadblock by identifying a gene in rice plants whose ...
... toxic pesticides" and "pesticides as a last resort" have ... scientific organizations the Weed Science Society of America ... Ecosystems Section of the Entomological Society of America (P-IE ... the pesticide component of an Integrated Pest Management (IPM) ...
... American Societies for Experimental Biology (FASEB) is rallying the ... facing the nation,s research agencies unless Congress acts before ... Institutes of Health (NIH) could lose $2.8 billion and ... Science Foundation (NSF) could be cut by nearly $600 ...
Cached Biology News:A better route to xylan 2A better route to xylan 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 2Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 3Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 4Scientists take objective look at terms 'least toxic pesticides' applied as 'last resort' 5FASEB urges biomedical research community to speak out against sequestration 2
... The RapidPlate 96/384 workstation offers precise 96 ... scalable format. Utilizing 100ul and 200ul disposable ... delivers excellent accuracy and precision across a ... rotary deck includes two positions that enable ...
... Rabbit Tissue Arrays contain 60 rabbit tissue samples ... contains 4 unstained slides and 1 hematoxylin and ... slide contains 15 different tissues from 4 rabbit ... per slide. Each tissue sample (or core) is ...
A univariate (peak height or area) quantitative multi-component analysis package....
... micro 10 represents a major advance in ... the benefits of large robotic liquid handlers ... dispenser. Dispensing accurate volumes ranging from 10mL ... has unique advantages not yet found in ...
Biology Products: